Holen Sie sich die Stockscreener-App
0.6958
3.44%
-0.0248
Handel nachbörslich:
.72
0.0242
+3.48%
Schlusskurs vom Vortag:
$0.7206
Offen:
$0.7381
24-Stunden-Volumen:
92,575
Relative Volume:
0.29
Marktkapitalisierung:
$10.01M
Einnahmen:
$500.00K
Nettoeinkommen (Verlust:
$-19.52M
KGV:
-0.1846
EPS:
-3.77
Netto-Cashflow:
$-19.47M
1W Leistung:
-16.04%
1M Leistung:
-29.40%
6M Leistung:
-50.30%
1J Leistung:
-27.14%
1-Tages-Spanne:
$0.6806
$0.7381
1-Wochen-Bereich:
$0.6669
$0.84
52-Wochen-Spanne:
$0.48
$3.65
Imunon Inc Stock (IMNN) Company Profile
Firmenname
Imunon Inc
Sektor
Branche
Telefon
(609) 896-9100
Adresse
997 LENOX DRIVE, LAWRENCEVILLE
Vergleichen Sie IMNN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IMNN | 0.6958 | 10.01M | 500.00K | -19.52M | -19.47M | -3.77 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Imunon Inc Aktie (IMNN) Neueste Nachrichten
FY2024 EPS Estimates for Imunon Boosted by Zacks Small Cap - Defense World
Analysts Set Expectations for Imunon Q1 Earnings - Defense World
Imunon, Inc. (NASDAQ:IMNN) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Imunon reveals promising ovarian cancer study results - Investing.com India
Earnings call: Imunon reveals promising ovarian cancer study results By Investing.com - Investing.com UK
Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ... - Yahoo Finance
Imunon, Inc. Reports Q3 2024 Earnings and Progress - TipRanks
Imunon Inc (IMNN) Quarterly 10-Q Report - Quartzy
Imunon presents data from Phase 2 OVATION 2 clinical trial - TipRanks
IMUNON Presents Positive Data from Phase 2 OVATION 2 - GlobeNewswire
IMUNON's Cancer Drug Shows 35% Survival Boost in Phase 2 Ovarian Cancer Trial | IMNN Stock News - StockTitan
Imunon sees cash runway into 3Q25 - TipRanks
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
IMUNON INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Imunon (IMNN) to Release Quarterly Earnings on Thursday - MarketBeat
IMUNON to Hold Third Quarter 2024 Financial Results and - GlobeNewswire
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 - Yahoo Finance
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of - GlobeNewswire
IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting - Marketscreener.com
Imunon’s stock rockets after ovarian cancer treatment’s positive trial results - MSN
Imunon reports inducement grant under NASDAQ listing rule - Yahoo Finance
Ex-Allstate Atty Named Biotech Co.'s General Counsel - Law360
Imunon Welcomes Susan Eylward as General Counsel, Strengthens Leadership Team - TipRanks
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary - Marketscreener.com
Imunon (NASDAQ:IMNN) Upgraded by EF Hutton Acquisition Co. I to “Strong-Buy” - Defense World
Imunon (NASDAQ:IMNN) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. I - MarketBeat
EF Hutton sets stock target on Imunon, initiates with buy rating - Investing.com Canada
Ratio Review: Analyzing Imunon Inc (IMNN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Imunon Inc (IMNN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Imunon (NASDAQ:IMNN) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
You might want to take a look at Imunon Inc (IMNN) now - SETE News
A review of IMNN’s current quarter earnings predictions - US Post News
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
IMNN (Imunon Inc) may reap gains as insiders became active recently - Knox Daily
UPDATEIMUNON’s Ovarian Cancer R&D Day to Feature - GlobeNewswire
IMNNImunon, Inc. Latest Stock News & Market Updates - StockTitan
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations - GlobeNewswire
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management - StockTitan
Imunon Inc. resumes ATM equity offering - Investing.com
Ratios Uncovered: Breaking Down Imunon Inc (IMNN)’s Trailing Twelve Months Metrics - The Dwinnex
Imunon Inc’s latest rating changes from various analysts - Knox Daily
The Attractiveness of Investing In Imunon Inc (IMNN) is Growing - Knox Daily
IMUNON to Host R&D Day on September 18th - GlobeNewswire
A significant driver of top-line growth: Imunon Inc (IMNN) - SETE News
Celsion Corporation : Celsion Announces Official ThermoDox® HEAT Study Results to be presented at the International Liver Cancer Association (ILCA) 2013 Annual Conference in Washington, D.C. on September 14, 2013 - Marketscreener.com
Imunon Inc [IMNN] Investment Guide: What You Need to Know - Knox Daily
Imunon Inc (IMNN) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Market Watch: Imunon Inc (IMNN)’s Noteworthy Gain, Closing at 1.14 - The Dwinnex
Q3 2024 EPS Estimates for Imunon, Inc. (NASDAQ:IMNN) Increased by Analyst - Defense World
Q3 2024 Earnings Estimate for Imunon, Inc. (NASDAQ:IMNN) Issued By Brookline Capital Management - Defense World
Finanzdaten der Imunon Inc-Aktie (IMNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Imunon Inc-Aktie (IMNN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tardugno Michael H | Executive Chairman of Board |
Aug 15 '24 |
Buy |
1.03 |
25,000 |
25,750 |
353,346 |
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):